Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ocug ...

Ocugen Shares Surge on Key Gene Therapy Validation

A significant milestone in Ocugen's development of a gene therapy for Stargardt disease has triggered a substantial rally in the company's stock. The catalyst was the publication of positive Phase 1 ...